|
Jazz Appears to Be Winner on Patent Claim Terms in Xyrem Suit
A district court judge has largely sided with Jazz Pharmaceuticals’ definitions for patents on its narcolepsy drug Xyrem, and the outcome looks like a “clear win” in Jazz’s legal struggle to prevent generic competition from Roxane Laboratories, one analyst says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives